Keyword: Ibrance

Pfizer breast-cancer fighter Ibrance posted a rare sales miss Tuesday, but it wasn't because Novartis and Lilly are stealing its share.

Pfizer’s Ibrance is OK'd to treat certain breast cancer patients who've relapsed, but new data suggests it may not help them live longer.

Just how big has the wave of new cancer drug ads been? Syneos analyzed DTC data from the past decade to find out.

Pfizer CEO Ian Read contends that the company's pipeline is strong enough to fuel growth. In other words, don't look for a "transformative" deal.

Eli Lilly’s first oncology campaign launched last week, putting the drugmaker on a growing list of pharma companies running DTC ads for cancer drugs.

​​​​​​​Debut ads helped drive list-toppers for pharma TV spend in February, with Ibrance, Otezla, Rexulti, Entresto and Eliquis entering the top 10.

It’s been only five months since Lilly breast cancer drug Verzenio launched, but it just racked up its third approval in a competitive market.

Trailing in the wake of Pfizer’s Ibrance, Novartis’ Kisqali is one step closer to nabbing a regulatory boost.

New discount deals with cost watchdogs in England have breast cancer drugs from Pfizer and Novartis on more equal footing than in the U.S.

Novartis breast cancer med Kisqali has struggled to gain traction in a field dominated by Pfizer's Ibrance. So it’s branching out.